Mehr lesen
Announcement of the complete sequencing of the human genome in April 2003 demonstrated the presence of thousands of targets for antisense oligonucleotides and opened the way to hundreds of preclinical animal studies and some 20 ongoing clinical trials. In this second edition of Antisense Therapeutics, a team of leading researchers and clinical scientists demonstrate the new reality of antisense and RNA inhibition for treating a broad range of diseases. The authors show how antisense oligonucleotides are being designed and studied in relation to hypertension, various cancers, inflammatory bowel disease, brain disorders, the blood-brain barrier, and drug delivery. Highlights include RNA-based therapies for many diseases, up-to-date methods and applications, and insight into the enormous potential to provide a new generation of drugs.
Highly practical and disease oriented, Antisense Therapeutics, Second Edition offers not only a primer for a new generation of drug discovery researchers, but also an illuminating exploration of the potential in exploiting RNA inhibition for novel human therapeutics.
Inhaltsverzeichnis
Part I. Introduction
Antisense Therapeutics: A Promise Waiting to be Fulfilled
M. Ian Phillips
Antisense Inhibition: Oligonucleotides, Ribozymes, and siRNAs
Y. Clare Zhang, Meghan M. Taylor, Willis K. Samson, and M. Ian Phillips
Part II. Cardiovascular
Local Application of Antisense for Prevention of Restenosis
Patrick L. Iversen, Nicholas Kipshidze, Jeffrey W. Moses, and Martin B. Leon
Antisense Therapeutics for Hypertension: Targeting the Renin-Angiotensin System
M. Ian Phillips and Birgitta Kimura
Antisense Strategies for the Treatment of Heart Failure
Sian E. Harding, Federica del Monte, and Roger J. Hajjar
Part III. Cancer
Clinical Studies of Antisense Oligonucleotides for Cancer Therapy
Rosanne M. Orr and F. Andrew Dorr
Antisense Therapy in Clinical Oncology: Preclinical and Clinical Experiences
Ingo Tamm
Radionuclide-Peptide Nucleic Acid Diagnosis and Treatment of Pancreatic Cancer
Eric Wickstrom, Xiaobing Tian, Nariman V. Amirkhanov, Atis Chakrabarti, Mohan R. Aruva, Ponugoti S. Rao, Wenyi Qin, Weizhu Zhu, Edward R. Sauter, and Mathew L. Thakur
Suppression of Pancreatic and Colon Cancer Cells by Antisense K-ras RNA Expression Vectors
Kazunori Aoki, Shumpei Ohnami, and Teruhiko Yoshida
Induction of Tumor Cell Apoptosis and Chemosensitization by Antisense Strategies
Manuel Rieber and Mary Strasberg-Rieber
Utility of Antioncogene Ribozymes and Antisense Oligonucleotides in Reversing Drug Resistance
Tadao Funato
Part IV. Blood-Brain Barrier
Transport of Antisense Across the Blood-Brain Barrier
Laura B. Jaeger and William A. Banks
Part V. Dermal
Transdermal Delivery of Antisense Oligonucletoides
Rhonda M. Brand and Patrick L. Iversen
Part VI. Drugs
Antisense Strategies for Redirection of Drug Metabolism: Using Paclitaxel as a Model
Vikram Arora
Part VII. Gastrointestinal
Antisense Oligonucleotide Treatment of Inflammatory Bowel Diseases
Bruce R. Yacyshyn
Part VIII. Hepatitis
Optimizing Electroporation Conditions for the Intracellular Delivery of Morpholino Antisense Oligonucleotides Directed Against the Hepatitis C Virus Internal Ribosome Entry Site
Ronald Jubin
Index
Zusammenfassung
A timely primer on the new reality of antisense and RNA inhibition for treating a broad range of diseases. The authors show how antisense oligonucleotides are being designed and studied in relation to hypertension, various cancers, inflammatory bowel disease, brain disorders, the blood-brain barrier, and drug delivery. Highlights include RNA-based therapies for many diseases, up-to-date methods and applications, and insight into the enormous potential to provide a new generation of drugs.
Zusatztext
From Reviews of the First Edition...
"...strongly recommended both to scientists already engaged in antisense research and to newcomers alike." -Trends in Biotechnology
"...enables an appreciation of the exciting possibilities this field offers for the development of new uniquely selective therapeutic agents via precisely designed inhibitors of the expression of disease associated genes." -Journal of Medicinal Chemistry
Reviews from the Second Edition...
"This book does an excellent job of showing the reader that antisense oligonucletoids could be valuable therapeutic drugs in the future." - Doody's Health Sciences Book
